Tribunal classifies 'Aswini Homeo Arnica Hair Oil' as medicament under Chapter 30

The Tribunal classified 'Aswini Homeo Arnica Hair Oil' (AHAHO) as a medicament under Chapter 30 of the Central Excise Tariff Act, 1985. The product's therapeutic properties, manufacturing under a Drug Licence, and recognition as a medicament led to this classification. Consequently, the Tribunal set aside duty demands and penalties, allowing the appeals with consequential reliefs.

---

---

Issues Involved:
1. Classification of the product 'Aswini Homeo Arnica Hair Oil' (AHAHO) as either a medicament or a cosmetic.
2. Applicability of concessional duty rates under specific notifications.
3. Imposition of penalties under Section 11AC read with Rule 25 of Central Excise Rules, 2002.

Detailed Analysis:

1. Classification of the Product:
The primary issue was whether AHAHO should be classified as a medicament under Chapter 30 or as a cosmetic under Chapter 33 of the Central Excise Tariff Act (CETA), 1985. The appellant argued that AHAHO is a mixture of four homeopathic medicines (Arnica, Cantharis, Pilocarpin, and Cinchona in a coconut oil base) used for therapeutic purposes such as treating hair loss, insomnia, and dandruff. The product is manufactured under a Drug Licence issued under Rule 25C of the Drugs & Cosmetics Rules, 1945, and is covered under Schedule K of the same rules, which pertains to drugs and not cosmetics.

The adjudicating authority, however, contended that AHAHO is not prescribed by a medical practitioner for curing diseases and is available over the counter, thus classifying it as a cosmetic. The authority also noted that the product label did not indicate mandatory sale conditions or dosage instructions.

Upon review, the Tribunal found that the product label mentioned therapeutic uses such as controlling hair fall, preventing dandruff, and inducing good sleep, which are indicative of medicinal properties. The Tribunal emphasized that the absence of specific disease names on the label does not disqualify a product from being a medicament. The Tribunal referenced several Supreme Court judgments, including Commissioner v. CIENS Laboratories and Puma Ayurvedic Herbal (P) Ltd. v. Commissioner of Central Excise, which supported the view that products with therapeutic properties, even if sold over the counter, should be classified as medicaments.

2. Applicability of Concessional Duty Rates:
The appellant claimed concessional duty rates under Notification No. 18/2012-CE dated 17.03.2012, applicable to homeopathic medicines. The Tribunal noted that the appellant had consistently classified the product as a medicament under Chapter 30 and had been granted such classification in previous proceedings. The Tribunal found no change in the nature of the product or its usage that would necessitate a reclassification under Chapter 33.

3. Imposition of Penalties:
The adjudicating authority had imposed penalties under Section 11AC read with Rule 25 of Central Excise Rules, 2002, based on the classification of AHAHO as a cosmetic. However, since the Tribunal concluded that AHAHO is a medicament, the basis for the penalties was invalid. The Tribunal held that the product should remain classified under Chapter 30, thus nullifying the demand for differential duty and associated penalties.

Conclusion:
The Tribunal concluded that AHAHO is a homeopathic medicine classifiable under Chapter 30 of the CETA, 1985. The product's therapeutic properties, its manufacturing under a Drug Licence, and its recognition by various authorities as a medicament were decisive factors. Consequently, the Tribunal set aside the impugned orders, annulled the duty demands and penalties, and allowed the appeals with consequential reliefs.

(Order pronounced on 31/01/2018 in open court)

---